Topomer CoMFA and virtual screening studies of azaindole class renin inhibitors

Combinatorial Chemistry and High Throughput Screening

Volumn 17, Issue 5, 2014, Pages 458-472

  Xiang, Yuhong ^a   Song, Jia ^a   Zhang, Zhuoyong ^a  

^a CAPITAL NORMAL UNIVERSITY   (China)

Author keywords

Fragment based drug design; Renin inhibitors; Surflex dock; Topomer Comfa; Topomer search; Virtual screening

Indexed keywords

AMIDE; AZAINDOLE CARBOXAMIDE; INDOLE DERIVATIVE; RENIN INHIBITOR; UNCLASSIFIED DRUG; 4-AZAINDOLE; ANTIHYPERTENSIVE AGENT; RENIN;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; CONSENSUS; DRUG BINDING; DRUG DESIGN; DRUG POTENCY; MOLECULAR DOCKING; MOLECULAR STABILITY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RANDOMIZATION; VALIDATION PROCESS; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM;

ANTIHYPERTENSIVE AGENTS; DRUG DESIGN; HUMANS; INDOLES; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RENIN;

EID: 84903748354     PISSN: 13862073     EISSN: 18755402     Source Type: Journal    
DOI: 10.2174/1386207317666140107094708     Document Type: Article

References (44)

1. Rastogi, A.; Rashid, M.; Wright, R.F. Reducing cardiorenal risk through combination therapy with a direct renin inhibitor. J. Clin. Hypertens. (Greenwich), 2011, 13, 848-855.
2. Fisher, N.D.L.; Meagher, E.A. Renin inhibitors. J. Clin. Hypertens. (Greenwich), 2011, 13, 662-666.
3. Subramanian, G. Computational modeling and design of rennin inhibitors. Bioorg. Med. Chem. Lett., 2013, 23, 460-465.
4. Webb, R.L.; Schiering, N.; Sedrani, R.; Maibaum, J. Direct rennin inhibitors as a new therapy for hypertension. J. Med. Chem., 2010, 53, 7490-7520.
5. Sheppard, R.J.; Schiffrin, E.L. Inhibition of the renin-angiotensin system for lowering coronary artery disease risk. Curr. Opin. Pharmacol., 2013, 13, 274-279.
6. Ritter, J.M. Dual blockade of the renin-angiotensin system with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). Br. J. Clin. Pharmacol., 2011, 71, 313-315.
7. Cheng, J.W.M. Aliskiren: Renin inhibitor for hypertension management. Clin. Ther., 2008, 30, 31-47
8. Jagadeesh, G.; Balakumar, P.; Stockbridge, N. How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders? Cell Signal, 2012, 24, 1583-1591.
9. Wood, J.M.; Maibaum, J.; Rahuel, J.; Grütter, M.G.; Cohen, N.C.; Rasetti, V.; Rüger, H.; Göschke, R.; Stutz, S.; Fuhrer, W.; Schilling, W.; Rigollier, P.; Yamaguchi, Y.; Cumin, F.; Baum, H.P.; Schnell, C.R.; Herold, P.; Mah, R.; Jensen, C.; O'Brien, E.; Stanton, A.; Bedigian, M.P. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun., 2013, 308, 698-705.
10. Lacombe, P.; Arbour, M.; Aspiotis, R.; Cauchon, E.; Chen, A.; Dubé D.; Falgueyret, J.P.; Fournier, P.A.; Gallant, M.; Grimm, E.; Han, Y.X.; Juteau, H.; Liu, S.; Mellon, C.; Ramtohul, Y.; Simard, D.; St-Jacques, R.; Tsui, G.C. 3,4-Diarylpiperidines as potent rennin inhibitors. Bioorg. Med. Chem. Lett., 2012, 22, 1953-1957.
11. Corminboeuf, O.; Bezencon, O.; Remeň, L.; Grisostomi, C.; Richard-Bildstein, S.; Bur, D.; Prade, L.; Strickner, P.; Hess, P.; Fischli, W.; Steiner, B.; Treiber, A. Piperidine-based rennin inhibitors: Upper chain optimization. Bioorg. Med. Chem. Lett., 2010, 20, 6291-6296.
12. Yuan, J.; Simpson, R.D.; Zhao, W.; Tice, C.M.; Xu, Z.R.; Cacatian, S.; Jia, L.Q.; Flaherty, R.T.; Guo, J.; Ishchenko, A.; Wu, Z.R.; McKeever, B.M.; Scott, B.B.; Bukhtiyarov, Y.; Berbaum, J.; Panemangalore, R.; Bentley, R.; Doe, C.P.; Harrison, R.K.; McGeehan, G.M.; Singh, S.B.; Dillard, L.W.; Baldwin, J.J.; Claremon, D.A. Biphenyl/diphenyl ether renin inhibitors: Filling the S1 pocket of renin via the S3 pocket. Bioorg. Med. Chem. Lett., 2011, 21, 4836-4843.
13. Chen, A.; Bayly, C.; Bezenon, O.; Richard-Bildstein, S.; Dubé D.; Dubé L.; Gagné S.; Gallant, M.; Gaudreault, M.; Grimm, E.; Houle, R.; Lacombe, P.; Laliberté S.; Lévesque, J.F.; Liu, S.; MacDonald, D.; Mackay, B.; Martin, D.; McKay, D.; Powell, D.; Remeň, L.; Soisson, S.; Toulmond, S. Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension. Bioorg. Med. Chem. Lett., 2010, 20, 2204-2209.
14. Sarver, R.W.; Peevers, J.; Cody, W.L.; Ciske, F.L.; Dyer, J.; Emerson, S.D.; Hagadorn, J.C.; Holsworth, D.D.; Jalaie, M.; Kaufman, M.; Mastronardi, M.; McConnell, P.; Powell, N.A.; Quin, J.; Van Huis, C.A.; Zhang, E.; Mochalkin, I. Binding thermodynamics of substituted diaminopyrimidine renin inhibitors. Anal. Biochem., 2007, 360, 30-40
15. Scheiper, B.; Matter, H.; Steinhagen, H.; Stilz, U.; Böcskei, Z.; Fleury, V.; McCort, G. Discovery and optimization of a new class of potent and non-chiral indole-3-carboxamide-based rennin inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 6268-6272.
16. Scheiper, B.; Matter, H.; Steinhagen, H.; Böcskei, Z.; Fleury, V.; McCort, G. Structure-based optimization of potent 4-and 6-azaindole-3- carboxamides as renin inhibitors. Bioorg. Med. Chem. Lett., 2011, 21, 5480-5486.
17. Matter, H.; Scheiper, B.; Steinhagen, H.; Böcskei, Z.; Fleury, V.; McCort, G. Structure-based design and optimization of potent rennin inhibitors on 5-or 7-azaindole-scaffolds. Bioorg. Med. Chem. Lett., 2011, 21, 5487-5492.
18. Subramanian, G.; Rao, S.N. An integrated computational workflow for efficient and quantitative modeling of renin inhibitors. Bioorg. Med. Chem., 2012, 20, 851-858.
19. Boehm, M.; Wu, T.Y.; Claussen, H.; Lemmen, C. Similarity searching and scaffold hopping in synthetically accessible combinatorial chemistry spaces. J. Med. Chem., 2008, 51, 2468-2480.
20. Cramer, R.D.; Cruz, P.; Stahl, G.; Curtiss, W.C.; Campbell, B.; Masek, B.B.; Soltanshahi, F. Virtual screening for R-groups, including predicted pIC50 contributions, within large structural databases, using Topomer CoMFA. J. Chem. Inf. Model., 2008, 48, 2180-2195.
21. Sheng, C.Q.; Zhang, W.N. Fragment Informatics and Computational Fragment-Based Drug Design: An Overview and Update. Med. Res. Rev., 2013, 33, 554-598.
22. Hoffer, L.; Renaud, J.P.; Horvath, D. In Silico Fragment-Based Drug Discovery: Setup and Validation of a Fragment-to-Lead Computational Protocol Using S4MPLE. J. Chem. Inf. Model, 2013, 53, 836-851.
23. Nisius, B.; Göller, A.H. Similarity-based classifier using topomers to provide a knowledge base for hERG channel inhibition. J. Chem. Inf. Model, 2009, 49, 247-256.
24. Politi, A.; Durdagi, S.; Moutevelis-Minakakis, P.; Kokotos, G.; Papadopoulos, M.G.; Mavromoustakos, T. Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases. Eur. J. Med. Chem., 2009, 44, 3703-3711.
25. Epps, D.E.; Cheney, J.; Schostarez, H.; Sawyer, T.K.; Prairie, M.; Krueger, W.C.; Mandel, F. Thermodynamics of the interaction of inhibitors with the binding site of recombinant human renin. J. Med. Chem., 1990, 33, 2080-2086
26. SYBYL version X1.2, St. Louis, MO, USA: Tripos Inc.
27. Xiang, Y.H.; Hou, Z.Y.; Zhang, Z.Y. Pharmacophore and QSAR Studies to Design Novel Histone Deacetylase 2 Inhibitors. Chem. Biol. Drug Des., 2012, 79, 760-770.
28. Topomer CoMFA® Manual, SYBYL, version X1.2, 1699 South Hanley Rd, St. Louis, MO 63144, USA: Tripos Inc, SD.
29. Yang, Y.; Qin, J.; Liu, H.X.; Yao, X.J. Molecular dynamics simulation, free energy calculation and structure-based 3D-QSAR studies of B-RAF kinase inhibitors. J. Chem. Inf. Model., 2011, 51, 680-692.
30. Zeng, G.H.; Fang, D.Q.; Wu, W.J.; Zhang, R.; Xie, W.G.; Wu, J.H.; Shen, Y. Binding conformations, QSAR, and molecular design of Alkene-3- quinolinecarbonitriles as Src inhibitors. Int. J. Quantum. Chem., 2013, 113, 1467-1478.
31. Ji, Y.J.; Shu, M.; Lin, Y.; Wang, Y.Q.; Wang, R.; Hu, Y.; Lin, Z.H. Combined 3D-QSAR modeling and molecular docking study on azacycles CCR5 antagonists. J. Mol. Struct., 2013, 1045, 35-41.
32. Li, Y.P.; Weng, X.; Ning, F.X.; Ou, J.B.; Hou, J.Q.; Luo, H.B.; Li, D.; Huang, Z.S.; Huang, S.L.; Gu, L.Q. 3D-QSAR studies of azaoxoisoaporphine, oxoaporphine, and oxoisoaporphine derivatives as anti-AChE and anti-AD agents by the CoMFA method. J. Mol. Graph. Model, 2013, 41, 61-67.
33. Yan, Y.L.; Li, Y.; Zhang, S.W.; Ai, C.Z. Studies of tricyclic piperazine/piperidine furnished molecules as novel integrin αvβ3/ αIIbß3 dual antagonists using 3D-QSAR and molecular docking. J. Mol. Graph. Model, 2011, 29, 747-762.
34. Wakasugi, M.; Gouda, H.; Hirose, T.; Sugawara, A.; Yamamoto, T.; Shiomi, K.; Sunazuka, T.; mura, S.; Hirono, S. Human acidic mammalian chitinase as a novel target for anti-asthma drug design using in silico screening. Bioorg. Med. Chem., 2013, 21, 3214-3220.
35. Weill, N.; Valencia, C.; Gioria, S.; Villa, P.; Hibert, M.; Rognan, D. Identification of Nonpeptide Oxytocin Receptor Ligands by Receptor-Ligand Fingerprint Similarity Search. Mol. Inform., 2011, 30, 521-526.
36. Available at: http://www.rcsb.org/pdb/.
37. Zhang, J.; Shan, Y.Y.; Pan, X.Y.; Wang, C.; Xu, W.F.; He, L.C. Molecular docking, 3D-QSAR studies, and in silico ADME prediction of p-aminosalicylic acid derivatives as neuraminidase inhibitors. Chem. Biol. Drug Des., 2011, 78, 709-717.
38. Yuan, J.T.; Pu, Y.P.; Yin, L.H. Docking-based three-dimensional quantitative structure-activity relationship (3D-QSAR) predicts binding affinities to aryl hydrocarbon receptor for polychlorinated dibenzodioxins, dibenzofurans, and biphenyls. Environ. Toxicol. Chem., 2013, 32, 1453-1458.
39. Jain, A.N. Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J. Comput. Aid Mol. Des., 2007, 21, 281-306
40. Vyas, V.K.; Ghate, M.; Goel, A. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors. J. Mol. Graph. Model, 2013, 42, 17-25.
41. Docking Suite Manual, SYBYL, version X1.2, 1699 South Hanley Rd, St. Louis, MO 63144, USA: Tripos Inc, SD.
42. Puntambekar, D.S.; Giridhar, R.; Yadav, M.R. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models. Eur. J. Med. Chem., 2008, 43, 142-154.
43. Puntambekar, D.S.; Giridhar, R.; Yadav, M.R. Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA. Eur. J. Med. Chem., 2006, 41, 1279-1292
44. Yadav, D.K.; Khan, F. QSAR, docking and ADMET studies of camptothecin derivatives as inhibitors of DNA topoisomerase-I. J. Chemom., 2013, 27, 21-33.